Trials / Completed
CompletedNCT03419962
Greek NIS Spiolto ELLACTO
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto® Respimat® [ELLACTO]
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,360 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MaxSpiolto® Respimat® 160 Characters... | as per the approved SmPC |
Timeline
- Start date
- 2018-03-19
- Primary completion
- 2018-11-09
- Completion
- 2019-04-03
- First posted
- 2018-02-05
- Last updated
- 2020-04-27
- Results posted
- 2020-04-27
Locations
15 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT03419962. Inclusion in this directory is not an endorsement.